dapivirine
Small moleculeexperimental
Dapivirine is a non-nucleoside reverse transcriptase inhibitor developed at Janssen Therapeutics. The International Partnership for Microbicides has held exclusive worldwide rights to dapivirine since 2014, building upon a 2004 royalty-free license to develop dapivirine-based microbicides for women in resource-poor countries. — Wikipedia
Clinical trial activity
45 trials · 18 clinical orgs · 0 marketing orgs
Phase 1
32
Phase 2
19
Phase 3
7
Phase 4
0
Earliest trial started Oct 1, 2004 (NCT00700284)
Timeline
Indications
Studied for
- Acquired Immunodeficiency Syndrome · Phase 1/Phase 2
- Contraception · Phase 1
- Contraception Behavior · Phase 1
- Healthy Volunteers · Phase 1/Phase 2
- Hemorrhage · Phase 1/Phase 2
- HIV · Phase 2
- HIV-1 · Phase 1/Phase 2
- HIV Infections · Phase 3
- Penile Diseases · Phase 1
- Pharmacokinetics · Phase 1/Phase 2
- Pharmacology · Phase 1
- Women · Phase 1
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
Reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(C)c(Nc2ccnc(Nc3ccc(C#N)cc3)n2)c(C)c1- Mol. weight
- 329.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDapivirine ↗
- ChEMBLCHEMBL70663 ↗
Also known as
- aids-105293
- aids-105293
- dapivirine
- dapivirine
- dapivirine
- dapivirine
- dapivirine
- r-147681
- r-147681
- tmc120
- tmc120
- tmc-120
- tmc-120
- tmc120-r147681
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06250504 | Phase 3 | Feb 27, 2024 | Africa Health Research Institute |
| NCT05416021 | Phase 1 | Aug 1, 2022 | FARMOVS Clinical Research Organisation, International Partnership for Microbicides, Inc. |
| NCT05041699 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2021 | International Partnership for Microbicides, Inc., National Institutes of Health (NIH) |
| NCT04140266 | Phase 3 | Feb 28, 2020 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID), University of Washington |
| NCT03965923 | Phase 3 | Oct 1, 2019 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID), University of Pittsburgh |
| NCT03467347 | Phase 1 | Jul 17, 2018 | International Partnership for Microbicides, Inc., National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH), National Institutes of Health (NIH) |
| NCT03393468 | Phase 1 | May 31, 2018 | National Institute of Allergy and Infectious Diseases (NIAID), University of Pittsburgh |
| NCT03234400 | Phase 1 | Dec 4, 2017 | International Partnership for Microbicides, Inc., National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT03074786 | Phase 2 | Nov 1, 2017 | Gilead Sciences, International Partnership for Microbicides, Inc., National Institutes of Health (NIH) |
| NCT03239483 | Phase 1 | Oct 26, 2017 | Badalona Hospital Germans Trias i Pujol, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02855346 | Phase 1 | May 3, 2017 | International Partnership for Microbicides, Inc., National Institutes of Health (NIH) |
| NCT02862171 | Phase 3 | Aug 1, 2016 | International Partnership for Microbicides, Inc. |
| NCT03044379 | Phase 1 | Sep 29, 2015 | International Partnership for Microbicides, Inc. |
| NCT02847286 | Phase 1 | Sep 1, 2015 | International Partnership for Microbicides, Inc. |
| NCT02808949 | Phase 1 | Feb 1, 2015 | International Partnership for Microbicides, Inc., University of Pittsburgh |
| NCT02858024 | Phase 1 | Jan 1, 2015 | International Partnership for Microbicides, Inc. |
| NCT02028338 | Phase 2 | Mar 1, 2014 | International Partnership for Microbicides, Inc., Microbicide Trials Network, National Institutes of Health (NIH) |
| NCT02010593 | Phase 2 | Dec 1, 2013 | International Partnership for Microbicides, Inc., National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01952561 | Phase 1 | Nov 1, 2013 | International Partnership for Microbicides, Inc. |
| NCT01924091 | Phase 1 | Sep 1, 2013 | International Partnership for Microbicides, Inc., Johns Hopkins University |
Showing 20 of 45 trials
Page 1 / 3
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| International Partnership for Microbicides, Inc. | Academic/Hospital | 40 | 40 | 4 | 2004 |
| International Partnership for Microbicides | Academic/Hospital | 14 | 0 | 4 | 2005 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 8 | 4 | 3 | 2012 |
| National Institutes of Health (NIH) | Government | 6 | 0 | 2 | 2014 |
| University of Pittsburgh | Academic/Hospital | 6 | 0 | 2 | 2011 |
| Johns Hopkins University | Academic/Hospital | 3 | 0 | 2 | 2013 |
| Ghent University | Academic/Hospital | 2 | 0 | 1 | 2004 |
| Tibotec | For profit | 2 | 0 | 1 | 2004 |
| University of Washington | Academic/Hospital | 2 | 0 | 1 | 2012 |
| Africa Health Research Institute | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Badalona Hospital Germans Trias i Pujol | Academic/Hospital | 1 | 0 | 1 | 2017 |
| California Family Health Council | Academic/Hospital | 1 | 0 | 1 | 2013 |
| FARMOVS Clinical Research Organisation | For profit | 1 | 0 | 1 | 2022 |
| Gilead Sciences | For profit | 1 | 0 | 1 | 2017 |
| Microbicide Trials Network | Academic/Hospital | 1 | 0 | 1 | 2014 |
| National Institute of Mental Health (NIMH) | Government | 1 | 0 | 1 | 2018 |
| The Fenway Institute | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Wits University | Academic/Hospital | 1 | 0 | 1 | 2012 |
18 organizations
Page 1 / 1